Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.

Also called NCT01341613

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 131 participants (enrolled count) (from the registry)
Sponsor
Micropharma Limited (from the registry)
Registry
  • NCT NCT01341613
Other papers using this trial's data
  • Evaluation of clinical safety and tolerance of a Lactobacillus reuteri NCIMB 30242 supplement capsule: a randomized control trial Regulatory toxicology and pharmacology : RTP, 2012-07 DOI, PubMed 22561556
  • Improvement of gastrointestinal health status in subjects consuming Lactobacillus reuteri NCIMB 30242 capsules: a post-hoc analysis of a randomized controlled trial Expert opinion on biological therapy, 2013-12 DOI, PubMed 24074303

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01341613. Randomized; quadruple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2011-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Cardioviva™ Probiotic Supplement Capsule Formulation
Condition
Hypercholesterolemia
Intervention (Dietary supplement)
Cardioviva™ supplement capsule
Intervention (Dietary supplement)
Placebo capsule
Lead sponsor
Micropharma Limited (class: industry)

Record details

Record id
cardio:ct-nct01341613
Content hash
29d3ed5fe528f7957d5a4d6ff0d6ddb5079436c6b92d4b202ea88da2dc7b8c2f